GleamWall
中文EN

MCUJF MEDICURE INC IFRS

Pharmaceutical Preparations · OTC · SEC CIK 1133519 · Reporting currency CAD · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY1.0%
TTM net income YoY-12.7%
TTM EPS YoY-11.1%
Revenue 3-yr CAGR0.2%
Net income 3-yr CAGR—

Margins

Gross margin59.7%
Operating margin—
Net margin-4.7%
FCF margin—
EBITDA margin—

Returns

ROE-5.1%
ROA-3.6%
ROIC (approx.)—
Asset turnover0.76x

Leverage & solvency

Liabilities / assets30.0%
Debt / equity0.00x
Current ratio1.89x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-1.33x
Accruals ratio-8.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Unit: CAD 2025Q1*2025-03-312024Q1*2024-03-31
Income statement
Revenue5.48M5.69M
Cost of revenue2.64M1.80M
Gross profit2.84M3.90M
R&D expense570,000676,000
SG&A expense1.10M1.21M
Pretax income-656,00082,000
Income tax38,000-31,000
Net income-694,00051,000
EPS (basic)-0.070.00
EPS (diluted)-0.070.00
Weighted avg. shares (diluted)10.44M10.50M
Balance sheet
Cash & equivalents7.22M—
Receivables4.46M—
Inventory3.91M—
Current assets15.78M—
PP&E, netmay include right-of-use assets (IFRS)1.00M—
Goodwill3.93M—
Intangibles8.96M—
Total assets29.78M—
Current liabilities9.24M—
Total liabilities9.68M—
Shareholders' equity20.09M20.50M
Cash flow statement
Operating cash flow656,000-132,000
Investing cash flow-542,000-87,000
Financing cash flow-89,000-76,000
Depreciation & amortization114,000104,000
Stock-based compensation36,00058,000

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· Amounts are in the company's reporting currency, CAD, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.